OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kohman Discusses Importance of Lung Cancer Screening

April 5th 2019

Leslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate University Hospital, Upstate Cancer Center, discusses the importance of lung cancer screening.

Dr. Lonial on Encouraging Data With Emerging Agents in Myeloma

April 5th 2019

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in myeloma.

Dr. Johnson on Promise of Combination Therapy in Melanoma

April 5th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma.

Dr. Dreicer on Biomarkers of Response to Immunotherapy in Urothelial Cancer

April 5th 2019

Robert Dreicer, MD, professor of medicine and urology, University of Virginia Health System, section chief, Medical Oncology, deputy director, UVA Cancer Center, discusses biomarkers of response to immunotherapy in patients with metastatic urothelial cancer.

Dr. Wallen on Surgery in Patients With Advanced Lung Cancer

April 4th 2019

Jason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses the role of surgery in patients with advanced-stage lung cancer.

Dr. Lee on Tailoring Treatment to Tumor Sidedness in mCRC

April 4th 2019

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment to tumor sidedness in patients with metastatic colorectal cancer.

Dr. Eber on Takeaways From the CARMENA Trial in mRCC

April 4th 2019

Paul R. Eber, MD, a urologist at Conrad-Pearson Clinic, discusses takeaways from the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Dr. Shaughnessy Discusses Unanswered Questions in DLBCL

April 4th 2019

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses unanswered questions in the field of diffuse large B-cell lymphoma (DLBCL).

Dr. George on the Importance of Collaboration in the Treatment of Uterine Sarcomas

April 4th 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of medicine, Harvard Medical School, discusses the importance of collaboration in the treatment of patients with uterine sarcoma.

Dr. Strickler on Genomic Variants Detected by Liquid Biopsies in GI Cancers

April 4th 2019

John Strickler, MD, assistant professor of medicine, Duke Cancer Institute, discusses genomic variants that can be detected by liquid biopsies in patients with gastrointestinal cancers.

Dr. Wright on Frontline Considerations in Locally Advanced Bladder Cancer

April 4th 2019

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses frontline considerations in patients with locally advanced, muscle-invasive bladder cancer.

Dr. Weckbaugh on the LIBRETTO-001 Trial in NSCLC

April 4th 2019

Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).

Dr. Cobleigh on Antibody-Drug Conjugates in Development in HER2+ Breast Cancer

April 4th 2019

Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.

Dr. Ferguson on Surgical Approaches in Cervical Cancer

April 3rd 2019

Sarah Ferguson, MD, FRCSC, associate professor of gynecologic oncology, University of Toronto, Princess Margaret Cancer Centre, discusses surgical approaches in patients with cervical cancer.

Dr. Rugo Discusses Regulatory Process Behind Biosimilars

April 3rd 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the regulatory process behind biosimilars in oncology.

Dr. Berlin on Potential Targets in Pancreatic Cancer

April 3rd 2019

Jordan D. Berlin, MD, Ingram Professor of Cancer Research, professor of medicine, VICC associate director for clinical research strategy, director, Phase I Program, gastrointestinal malignancies, clinical trials, Department of Medicine, Vanderbilt University Medical Center, discusses potential targets in pancreatic cancer.

Dr. Salem on the Results of the MyPathway Trial in mCRC

April 3rd 2019

Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).

Dr. George on the Impact of Immunotherapy on TKIs in RCC

April 3rd 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the impact of immunotherapy on TKIs in renal cell carcinoma (RCC).

Dr. Goldberg Discusses the Diagnosis of Mesothelioma

April 2nd 2019

Sarah B. Goldberg, MD, MPH, assistant professor of medicine, Yale School of Medicine and Yale Cancer Center, discusses the diagnosis of patients with mesothelioma.

Dr. Armstrong Discusses Findings of ARCHES Trial in Prostate Cancer

April 2nd 2019

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses findings from the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.